New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
07:28 EDTTGTXTG Therapeutics added to Focus List at Roth Capital
Roth Capital added TG Therapeutics to the Focus List based on exceptions the remainder of 2104 will be transformational with upcoming data catalysts and improved visibility from the competitive landscape. Shares are Buy rated with a $15 price target.
News For TGTX From The Last 14 Days
Check below for free stories on TGTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
10:30 EDTTGTXTG Therapeutics capitlal raise unlikely, says Roth Capital
Subscribe for More Information
September 15, 2014
14:10 EDTTGTXTG Therapeutics SPA for CLL study earlier than expected, says Ladenburg
Ladenburg said TG Therapeutics reached an agreement with the FDA regarding a Special Protocol Assessment, or SPA, for a trial of its combo treatment for Chronic Lymphocytic Leukemia, or CLL, "quite ahead" of the firm's December expectation. The firm believes there is a relatively high probability for TG's combo to meet the specified primary endpoint and increased its price target on the stock to $22 from $18.
07:03 EDTTGTXTG Therapeutics announces SPA agreement with FDA for Phase 3 trial of TG-1101
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use